SCHEMBL5651818

SCHEMBL5651818

COc1cc(C(=O)NN2CCCCC2)ccc1-c1nc2cc(Cl)c(F)cc2[nH]1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FOXO1 Q12778 2/20 0.42
RHEB Q15382 1/20 0.42
HDAC6 Q9UBN7 1/20 0.41
PRSS12 P56730 3/20 0.41
PRKAG1 P54619 1/20 0.41
PRKAA1 Q13131 1/20 0.41
PRKAB1 Q9Y478 1/20 0.41
PDE7A Q13946 1/20 0.40
KDR P35968 1/20 0.40
HDAC11 Q96DB2 1/20 0.40
CLK1 P49759 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CNR1 P21554 1/20 0.39
CNR2 P34972 1/20 0.39
AMY1A P0DUB6 1/20 0.39
USP2 O75604 1/20 0.38
POLB P06746 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5653611 0.93 RHEB (0.49) FOXO1RHEBHDAC6PRSS12PRKAG1
SCHEMBL5652578 0.91 SIRT2 (0.42) RHEBPRSS12PRKAG1PRKAA1PRKAB1
SCHEMBL5650908 0.90 FOXO1 (0.43) FOXO1RHEBHDAC6PRSS12PRKAG1
SCHEMBL5651532 0.89 KDR (0.43) RHEBHDAC6PRSS12KDRCNR1
SCHEMBL5650474 0.88 CNR1 (0.41) RHEBPRSS12KDRCNR1CNR2
SCHEMBL5652794 0.86 PRSS12 (0.41) RHEBHDAC6PRSS12KDRCNR1
SCHEMBL5653237 0.85 HDAC6 (0.46) FOXO1HDAC6PRKAG1PRKAA1PRKAB1
SCHEMBL5650995 0.84 PRSS12 (0.47) RHEBHDAC6PRSS12KDRCNR1
SCHEMBL5653630 0.83 PRSS12 (0.54) RHEBHDAC6PRSS12KDR
SCHEMBL5648605 0.83 RHEB (0.45) RHEBPRSS12PRKAG1PRKAA1PRKAB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 FOXO1 252/4885RHEB 946/4885HDAC6 537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.